First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Michele Maio, Erika Richtig et al.|Journal of Clinical Oncology|2023Cited by 25